FDA Oversteps Its Bounds In Guidance On Research-Only Tests, Firms Say
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics companies say recent draft guidance on research-use and investigational tests oversteps FDA’s authorities by asking firms to police how customers ultimately use these products.
You may also be interested in...
Knowledge Is Not Enough For Enforcement In FDA’s Final Research-Use Dx Guidance
Companies are at risk of enforcement if they take direct steps to encourage use of their research-use or investigational-use only tests for clinical diagnostic indications, according to the guidance. But, in response to public comments, FDA removed references that a company knowing or having “reason to know” that a lab is inappropriately using a test is grounds for enforcement.
Knowledge Is Not Enough For Enforcement In FDA’s Final Research-Use Dx Guidance
Companies are at risk of enforcement if they take direct steps to encourage use of their research-use or investigational-use only tests for clinical diagnostic indications, according to the guidance. But, in response to public comments, FDA removed references that a company knowing or having “reason to know” that a lab is inappropriately using a test is grounds for enforcement.
Attorneys See FDA Rulemaking By Guidance In NDI Notification Draft
FDA’s use of sweeping guidance documents, such as the NDI notification draft, faces criticism from industry attorneys. The recent Franck’s Lab case, which FDA lost, could serve as a precedent for legal challenges of agency enforcement that tracks guidance.